Mantle cell lymphoma (MCL) is an uncommon type of non- Hodgkin lymphoma (NHL) comprising <10% of all newly diagnosed patients. Classified as an aggressive NHL subtype, MCL has the worst prognosis of B-cell subt
lymphoma is nuclear expression of cyclin D1 as a result of an underlying chromosomal translocation involving IGH and CCND1 [t(11;14)] (see Mantle Cell Lymphoma of the Gastrointestinal Tract, Chapter 5, and Mantle Cell Lymphoma, Chapter 13, for additional information on mantle cell lymphoma). ...
Mantle cell lymphoma (MCL) is a distinctive type of non-Hodgkin’s lymphoma composed of small-to-medium–sized lymphocytes that coexpress pan–B-cell antigens and the pan–T-cell antigen, CD5. The chromosome translocation t(11;14)(q13;q32) results in activation of the PRAD-1/cyclin-D1...
Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops. In this study, we assessed the efficacy of
Mantle cell lymphoma (MCL) is no longer a hopeless disease. Considered to carry a uniformly dismal prognosis so far, during the last years it has been rediscovered as a heterogeneous clinical and biological entity. Such a complexity has been highlighted
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer ...
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma. Michael Wang, MD Five-year follow-up data from cohorts 1 and 2 of the phase 1/2 ZUMA-2 trial (NCT02601313) showed that treatment with the CAR T-cell therapy brexucabta...
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108. 9. Geisler CH, Kolstad A, Laurell A, et al. The mantle cell lymphoma international prognostic index (MIPI) is ...
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable. The majority of pa
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant